Nursing care
H2 Blockers: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 5 min read · Updated September 2026
Short answer
H2 blockers such as famotidine reduce stomach acid by blocking histamine at the parietal cell's H2 receptor, but the effect is slower to establish and less complete than a proton pump inhibitor's. That gap is why they are used for maintenance acid control and mild reflux rather than as the drug reached for in an active bleed or severe erosive disease. Famotidine is now the preferred agent in this class.
Why this drug and not another
H2 blockers work by competing with histamine at the H2 receptor on gastric parietal cells, one of three pathways that drive acid secretion alongside gastrin and acetylcholine. Blocking one pathway rather than the pump itself is why acid suppression with this class is partial and shorter-acting than a PPI's, and why tolerance can develop with continuous use as the other pathways partly compensate.
That weaker, slower profile is exactly why an H2 blocker is chosen: for mild to moderate GERD, for maintenance therapy once an acute ulcer has been treated with something stronger, or for a patient who cannot tolerate a PPI. It is not the drug reached for in active GI bleeding, severe erosive oesophagitis, or Zollinger-Ellison syndrome, where a PPI's near-complete acid blockade is needed instead.
Administration and timing
Famotidine can be given with or without food, once or twice daily depending on the indication, which is a simpler regimen than the empty-stomach timing a PPI requires. IV famotidine is available for patients who cannot take oral medication and for stress ulcer prophylaxis in the acute setting.
Onset of acid suppression with an H2 blocker is within an hour, faster than most people expect, but the ceiling on how much acid it can block is lower than a PPI's, and the effect wanes over a dosing interval in a way a once-daily PPI's does not. Dose reduction is required in renal impairment, since famotidine is renally cleared and accumulation increases the risk of central nervous system effects, particularly in older adults.
Monitoring parameters
Track symptom relief against the indication: reduction in heartburn frequency for GERD, healing on follow-up endoscopy for ulcer disease, or absence of new GI bleeding in a prophylaxis context. Renal function should be checked before starting and periodically during use, since dose adjustment for reduced creatinine clearance is a real prescribing consideration, not a formality.
In older adults or anyone with renal impairment, watch for confusion, agitation or altered mental status, which reflect drug accumulation rather than a new neurological event. This is a well-documented but under-recognised effect of the class, and it is worth ruling out before ordering a broader delirium workup in a patient who was started on an H2 blocker in the days before symptoms began.
Adverse effects to report
Headache and mild GI upset are the most common effects and rarely need intervention. Confusion, disorientation or agitation, especially in an older adult or a patient with reduced renal clearance, should be reported and considered drug-related until proven otherwise, since this reaction can be mistaken for an unrelated acute confusional state.
Cimetidine, an older H2 blocker still occasionally seen, carries a distinct risk profile including gynaecomastia and a much higher burden of drug interactions through CYP450 inhibition; these are not class-wide effects and should not be attributed to famotidine. Any rash, unexplained bruising or signs of blood dyscrasia, while rare, warrant prompt reporting for any drug in this class.
Contraindications and cautions
Known hypersensitivity to the specific H2 blocker is the clear contraindication; cross-reactivity between agents in the class is uncommon but should be checked when switching a patient who has had a prior reaction. Renal impairment is a caution rather than an absolute contraindication, but it changes the dose, and prescribing at a standard dose in significant renal impairment is a preventable error.
Ranitidine was withdrawn from the market after contamination with a probable carcinogen was found in the product itself, not because of a class-wide safety issue, so do not extend that caution to famotidine or cimetidine. Use caution in patients with hepatic impairment, and be aware that H2 blockers can mask the symptoms of gastric malignancy by relieving pain without addressing an underlying lesion, which is why persistent or worsening symptoms despite treatment need escalation for investigation rather than a dose increase.
Teaching points the exam tests
The exam-favourite distinction is speed and strength: H2 blockers act faster than a PPI at onset but suppress acid less completely and for less time, which is why they are the maintenance drug and a PPI is the one used for active disease or bleeding. Expect a question that gives a scenario and asks which class fits, rather than asking you to name the drug directly.
Patients should be told to take the dose consistently, report confusion or unusual drowsiness rather than dismissing it as unrelated, and know that this drug does not require the empty-stomach timing a PPI does. Teach patients not to substitute an H2 blocker for a PPI on their own initiative if a prescriber specifically chose the stronger drug for a reason such as active bleeding or erosive disease, since the two classes are not interchangeable despite treating the same underlying problem.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our gastrointestinal practice questions are the closest set to what this page covers.
Common questions
Why would a patient be switched from a PPI to famotidine?
Common reasons include stepping down after an acute ulcer or erosive oesophagitis has healed, intolerance to a PPI, or a prescriber choosing to limit long-term PPI exposure because of its association with reduced bone density and B12 deficiency. Famotidine's simpler dosing and lower interaction burden also make it easier to manage in patients on complex medication regimens.
Is confusion in an older patient on famotidine an emergency?
It should be reported and assessed promptly, but it is a known and often reversible effect of drug accumulation in reduced renal clearance rather than a sign of a new acute neurological event on its own. Renal function and dosing should be reviewed, and other causes of confusion should still be ruled out rather than assumed away.
Why was ranitidine taken off the market and does that apply to famotidine?
Ranitidine was withdrawn after testing found the product could contain unacceptable levels of a probable human carcinogen, an issue specific to that drug's formulation and stability, not a mechanism shared by the H2 blocker class. Famotidine is unaffected by that recall and remains the preferred H2 blocker in current practice.
Does famotidine need to be taken on an empty stomach like a PPI?
No. It can be taken with or without food, which is one of the practical differences nurses use to distinguish it from a PPI when teaching patients or answering exam questions about timing.